Dyne Therapeutics, Inc. has announced that its investigational therapeutic, DYNE-251, for Duchenne muscular dystrophy (DMD), has been granted FDA orphan drug and rare pediatric disease designations.
Dyne Therapeutics Inc. presented their most recent work to advance novel therapeutics for facioscapulohumeral muscular dystrophy (FHSD). FSHD is an autosomal dominant genetic disorder characterized by ...
Dyne Therapeutics Inc. is advancing novel therapeutics for people living with genetically driven neuromuscular diseases. Representatives from the company recently presented a poster showcasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results